RE:Audience survey of uro-oncologists
I'm posting this comment as part of an old post so that the photo gets reposted.
Recall that the audience survey for the competitors was not great back in the spring. This was to audience of uro-oncologists.
Anktiva + BGG combo was approved end April of this year. The company said that at the time of approval that they had 20,000 doses ready to go.
In June, they reported "ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives"
Cost for one instillation in one patient is around 37,700 (quoted) with each treatment course being 6 weekly doses at start followed by 3 weekly doses at months 4, 7, 10, 13 and 19.
So 37,700 x 6 = 226200 for the 6 week induction. Usually drug companies and medicare negotiate around 25% discount on sticker so let's say 170,000 per patient induction.
IBRX just posted earnings for the most recent quarter. Market cap of 2.75 Billion and earnings last quarter were 1m dollars. Yikes. That means they treated something like 6-10 patients maybe.
My hunch is that when the urologist presents the data and says that it will require this many instillations and there is a 1/4 chance it will come back in next two years, it has not been that appealing.
So clearly the void for NMBIC treatment has not been filled by adstiladrin or anktiva yet. Good news for TLT as long as they can pitch it properly.
The real competition maybe Gem/Doc. However, my understanding is Gem/Doc is an ongoing monthly protocol and the DOR rates are not great once you stop the monthly instillations. Someone else may confirm that for me.
So in summary, IBRX launched the best competitor yet and it has NOT been a seller.